Tranexamic Acid for Melasma and Dark Spots: What Does the Clinical Evidence Really Show?
Ingredient science · Clinical evidence · 29 October 2026

Tranexamic Acid for Melasma and Dark Spots: What Does the Clinical Evidence Really Show?

A pigment-fading ingredient that started its career as a medicine to reduce bleeding sounds unlikely. Yet tranexamic acid has become one of the most interesting molecules in pigmentation-focused skincare. The question is not whether it has a clever mechanism. The question is how much of that science survives contact with a real face—and a real serum.

Melasma, post-inflammatory hyperpigmentation (PIH) and ordinary sun spots can look similar in the mirror, but they do not share exactly the same biology. That distinction matters when choosing treatment. Recent randomized trials and a 2026 systematic review have given us better data on tranexamic acid (TXA), particularly for melasma. They have also revealed why a promising ingredient should not be mistaken for a guaranteed result from any bottle bearing its name.

Dermatologist's short answer: Topical TXA is a reasonable option to consider for melasma and uneven pigmentation, especially as part of a consistent routine with photoprotection. Evidence is encouraging but mixed; the best-studied concentrations and formulations are not interchangeable with every commercial serum. For post-acne brown marks, the clinical evidence is less direct than it is for melasma.

What is tranexamic acid—and why would it affect pigmentation?

Tranexamic acid is a synthetic derivative of the amino acid lysine. Medically, it is an antifibrinolytic: it binds to plasminogen and limits its activation to plasmin, helping prevent the breakdown of blood clots. In dermatology, researchers have investigated a different consequence of this pathway.

After ultraviolet exposure, keratinocytes can increase plasmin-related signalling. Plasmin is linked to the release of arachidonic acid and downstream mediators such as prostaglandins, which may stimulate neighbouring melanocytes to produce more pigment. By interfering with this pathway, TXA may reduce some of the UV-induced signals that encourage melanogenesis. Researchers have also explored effects on vascular and inflammatory pathways involved in melasma. These mechanisms are biologically plausible, but not every proposed pathway has been demonstrated at the concentrations that actually reach living skin after ordinary cosmetic application. [1]

Importantly, TXA is not an exfoliating acid. Unlike glycolic or salicylic acid, its primary proposed action is not to remove surface skin cells. The word “acid” describes its chemistry, not a peeling effect.

Why pair tranexamic acid with niacinamide?

Niacinamide (vitamin B3) works at a different step in pigmentation: experiments suggest it reduces the transfer of melanin-containing melanosomes from melanocytes to surrounding keratinocytes. An early human study found that a 5% niacinamide moisturiser reduced visible hyperpigmentation compared with its vehicle, while the mechanistic work showed a 35–68% reduction in melanosome transfer in cell-culture models—not a 35–68% reduction in facial dark spots. [2]

Combining TXA and niacinamide therefore makes mechanistic sense. But two interesting mechanisms do not automatically add up to a clinically superior finished serum. That requires a controlled trial of the formulation itself.

What did the recent clinical studies actually find?

Clinical evidence at a glance

Four useful comparisons, each answering a different question. Outcomes use different scales, formulations and controls, so the percentages below should not be compared as if the studies tested the same product.

Study Participants and treatment Main result What it cannot prove
Ghasemiyeh et al., 2025 99 randomized; 77 completed. Niosomal TXA 2% + niacinamide 2%, conventional TXA 5% + niacinamide 4%, or hydroquinone 4%; 3 months. All groups improved. Niosomal group: 66.72% reduction in mMASI; conventional group: 62.40%. No statistically significant between-group efficacy difference. Does not establish equivalence or prove that any retail TXA/niacinamide serum performs the same.
Heidary et al., 2025 50 women; oral TXA 250 mg twice daily versus topical TXA 5% cream twice daily; 12 weeks. MASI decreased 58.86% (oral) versus 50.88% (topical); between-group difference not statistically significant. No placebo arm; a non-significant difference does not prove equal efficacy. The publication has a subsequent correction notice.
Janney et al., 2019 100 patients; topical TXA 5% solution versus hydroquinone 3% cream; 12 weeks, single-blind. MASI decreased 27.0% versus 26.7%, respectively; no significant between-group difference. Short follow-up and no vehicle arm; does not demonstrate superiority to hydroquinone.
Scabine Pessotti et al., 2026 Systematic review: 32 RCTs, 2,376 participants, mixed oral/topical/intradermal regimens and combinations. Overall TXA versus placebo: SMD −0.36 (95% CI −0.77 to 0.06), not statistically conclusive in the main pooled comparison. High heterogeneity and mixed routes prevent a simple estimate for a 4% cosmetic serum.

mMASI/MASI are clinical measures of melasma area and severity; lower scores indicate improvement. SMD is a standardized mean difference; a confidence interval crossing zero does not establish a clear overall treatment effect. Sources: 2025 RCT, 2025 oral-versus-topical RCT, 2019 RCT, 2026 review.

1. The 2025 formulation trial: does the delivery system matter?

Could a cream with less TXA work as well if it delivered the ingredients differently? A study published in Scientific Reports on 28 November 2025 explored that question in 99 people with melasma. Participants were randomly assigned to three creams, with 33 people in each group: niosomal 2% TXA + 2% niacinamide, conventional 5% TXA + 4% niacinamide, or 4% hydroquinone. “Niosomal” means the ingredients are packaged in tiny carriers designed to influence how they reach the skin. The trial was double-blind, meaning treatment identities were concealed from both participants and the researchers assessing them. Seventy-seven people completed the three-month treatment, and 69 returned for a short-term check after stopping. [3]

All three groups improved. Researchers tracked how much of the face melasma affected and how pronounced it was using the modified Melasma Area and Severity Index (mMASI): a lower score means less severe melasma. They also measured skin pigment and asked about quality of life; those measures improved too. The average mMASI score fell by 66.72% in the niosomal group and 62.40% in the conventional TXA/niacinamide group. Those percentages describe changes in a clinical score, not how much lighter someone’s skin became. Although the numbers look different, the main pigmentation results showed no statistically significant difference between groups: the study could not confidently distinguish their effects from chance variation. More local skin reactions were reported with hydroquinone (p = 0.033); this p-value indicates statistical evidence for a difference in reactions, not the percentage of people affected.

99randomized participants
77completed 3 months
66.72%mMASI reduction, niosomal arm

The interesting finding is that the cream with lower ingredient concentrations produced similar observed results to the conventional, higher-concentration cream. That makes the tiny delivery carriers, called niosomes, worth studying further. But it does not prove that niosomes caused the result. Both TXA and niacinamide concentrations differed between the creams. There was also no matching cream base without the active ingredients (a vehicle control), or a comparison of niosomal and conventional creams with the same ingredient concentrations. Those missing comparisons make it hard to separate the effect of the carriers from the rest of the formula. Another limitation: 22 of 99 participants left before treatment ended, which can affect how confidently we interpret the findings. And a one-month check after stopping is too short to tell us whether improvement lasts or melasma returns over the longer term.

2. Is topical TXA comparable to oral TXA?

Can a cream offer improvement similar to tablets? In a randomized trial at a single centre, published in September 2025, 50 women with melasma were assigned to one of two treatments: oral TXA 250 mg twice daily or a 5% TXA cream applied twice daily for 12 weeks. Researchers used MASI, a score that combines the area affected by melasma with its severity. The score fell by 58.86% in the tablet group and 50.88% in the cream group. The larger numerical improvement with tablets was not statistically significant, so this study could not confidently show that one treatment worked better. One participant using the cream stopped because of sensitivity. [4]

For someone considering a cream, that is an encouraging finding—but it comes with limits. There was no vehicle-control group using the cream base without TXA, so the trial could not show how much improvement came from TXA itself compared with that base. With only 50 women, the study may also have missed a real difference between treatments. “No statistically significant difference” therefore does not establish that the two treatments are equally effective. The publication also carries a later correction notice. And effectiveness is only part of the decision: how well a facial cream is tolerated tells us nothing about the safety of taking oral TXA, which has different risks.

3. What does the 2026 systematic review change?

What happens when researchers look beyond individual trials? A systematic review and meta-analysis published on 6 January 2026 brought together 32 randomized trials involving 2,376 people with melasma. A meta-analysis combines study results to look for an overall pattern. Because trials used different scoring systems, the researchers expressed the combined effect as a standardized mean difference (SMD), rather than a percentage improvement. In the main TXA-versus-placebo comparison, the SMD was −0.36 (95% CI −0.77 to 0.06). The negative value points towards benefit from TXA, but the 95% confidence interval—the range expressing uncertainty around the estimate—crosses zero, the point representing no difference. The result therefore does not clearly establish an overall benefit over placebo. The comparison of TXA plus hydroquinone against hydroquinone alone favoured the combination (reported SMD −1.59; 95% CI −2.51 to −0.66). However, the studies’ findings varied enormously (I² = 97%). That number describes inconsistency between studies, not a 97% improvement or success rate. [5]

There is another reason to read the headline cautiously: this review combined TXA taken by mouth, applied to the skin and injected into the skin, as well as treatments involving procedures. Those approaches do not deliver TXA in the same way, so their combined results cannot predict what a particular cosmetic serum will do. Also, although the review appeared in 2026, its searches were updated only through January 2024. The later 2025 trials discussed above were therefore not included. The useful takeaway is that some treatment regimens appear helpful, but uncertainty remains about how reliable the evidence is, how much each delivery route helps and whether the results can be consistently repeated.

How to interpret the numbers: A 60% improvement in a trial's melasma severity score is not the same as 60% lighter skin, 60% fewer dark spots or a predicted result for a particular serum. It is a change in a defined clinical scoring system under that study's conditions.

What concentration of tranexamic acid should a serum contain?

Human studies have investigated topical concentrations ranging roughly from 2% to 5% in creams, solutions and delivery-enhanced formulations, with some studies using higher concentrations. There is no universally established optimal concentration for all cosmetic products, skin types or pigmentation diagnoses. A higher percentage is not automatically more effective if the vehicle cannot deliver the ingredient appropriately—or if the formula irritates the skin enough to worsen pigmentation.

The 2025 niosomal study is a useful reminder: a 2% TXA formulation with a particular carrier was investigated alongside a conventional 5% TXA cream, but their niacinamide concentrations and vehicles also differed. Formulation quality, stability, tolerability and application consistency matter alongside the percentage on the label.

And there is another distinction: the evidence is strongest for melasma, a chronic, hormonally and light-influenced pigmentary disorder. Evidence for post-acne brown marks (PIH) is biologically plausible but supported by fewer high-quality, product-specific trials. Red post-acne marks (post-inflammatory erythema) involve vascular changes rather than excess melanin and may need a different approach.

Can professional procedures make TXA work better?

Possibly, but a procedure changes both how TXA reaches the skin and the risks involved. A 2025 trial used a useful comparison: each of its 27 participants received topical 5% TXA twice daily on both sides of the face, while one side also received three 1540-nm non-ablative fractional laser sessions at four-week intervals. This “split-face” design lets researchers compare treatments within the same person. Immediately after treatment, the laser-plus-TXA side improved more on mMASI, the score for melasma area and severity (p = 0.029, indicating a statistically significant difference). But one and three months later, there was no longer a statistically significant difference between the sides. Melasma returned on both sides during follow-up. The initial extra improvement therefore did not translate into a clearly demonstrated lasting advantage. [6]

This is not evidence that applying an ordinary serum after home microneedling is safe or effective. Laser-assisted delivery and professional microneedling can change penetration, inflammation and the risk of post-inflammatory pigmentation. For melasma-prone skin, procedures need careful individual assessment.

The overlooked step: visible light and daily sunscreen

Melasma is notoriously prone to relapse. UV radiation matters, but visible light—especially in more pigmented skin—can also contribute to persistent pigmentation. That is why a sunscreen with strong UVA/UVB protection is essential, and why an iron-oxide-containing tinted sunscreen can be particularly useful when visible-light protection is a priority.

Does a tint make a measurable difference? A randomized summer study published in 2025 compared two SPF50+ sunscreens in 42 women with melasma: a tinted sunscreen designed to protect against visible light and an untinted sunscreen with similar UV protection. 41 women completed five months. The researchers assessing outcomes did not know which sunscreen each woman had been assigned—an approach called investigator blinding. Both groups improved on mMASI, the clinical score for melasma area and severity, with no statistically significant difference between groups. A separate, objective measurement looked at the colour contrast between melasma patches and unaffected skin; that contrast improved more clearly in the tinted group. In everyday terms, the patches became less distinct by this measurement, even though the clinical severity scores did not show a clear advantage for either sunscreen. The findings need caution: the sample was small, the groups differed in some characteristics at the start, and the sunscreen manufacturer funded the study. [7]

Not every tinted BB cream has a validated visible-light protection factor. For pigment-prone skin, prioritize generous daily UVA/UVB protection, and consider a suitable iron-oxide tint on top or a tested tinted sunscreen. Makeup applied in a thin cosmetic layer is not a reliable substitute for the amount of sunscreen used in SPF testing. For a related discussion, see our sunscreen and vitamin D article.

How I would build a pigmentation-focused routine

For mild uneven pigmentation, consistency is usually more valuable than layering five brightening actives at once. In the morning, use a gentle cleanser if needed, a well-tolerated pigment-focused serum, moisturiser as required and a generous layer of broad-spectrum sunscreen. Reapply sunscreen according to exposure, particularly outdoors. For melasma, consider visible-light protection as well.

In the evening, cleanse gently, apply your selected active and follow with moisturiser. Start a high-niacinamide formula slowly if your skin is reactive; 10% niacinamide can cause flushing or stinging in some people. Reassess after approximately 8–12 weeks, taking consistent photographs in similar lighting. Melasma often needs longer-term maintenance and, in more pronounced cases, a dermatologist-guided treatment plan.

Azelaic acid is a reasonable alternative for people whose main concerns include acne, rosacea or post-inflammatory brown marks. Prescription-strength azelaic acid has a stronger direct evidence base for some of these indications than a 10% cosmetic serum, so concentrations should not be treated as interchangeable. If you have rapidly changing, unusual or asymmetric pigmentation, get the diagnosis checked rather than assuming every spot is melasma.

Relevant skincare options at More About Skin

Each product below contains tranexamic acid. The two facial serums offer different TXA concentrations; the eye cream is a separate option for the eye contour. Choose one facial serum rather than layering both. These products are selected for their ingredient rationale—the trials above did not test these finished formulas. All three were active and in stock when checked on 29 October 2026; availability and prices can change.

Original ANUA Niacinamide 10% + TXA 4% Serum packaging
ANUA

Niacinamide 10% + TXA 4% Serum (2024 Version)

Directly relevant to pigment-focused routines. The disclosed 4% TXA and 10% niacinamide are not evidence that this particular serum reproduces clinical trial outcomes. Introduce gradually if sensitive.

CHF 19.90
VIEW PRODUCT
Original NINE LESS B-Boost 10% Niacinamide Serum packaging
NINE LESS

B-Boost 10% Niacinamide Serum

An alternative facial serum with 2% tranexamic acid, 10% niacinamide and 0.5% ascorbyl glucoside. The lower TXA percentage does not establish lower effectiveness; results depend on the complete formula. Introduce gradually if sensitive.

CHF 15.85
VIEW PRODUCT
Original MARY & MAY Tranexamic Acid + Glutathione Eye Cream packaging
MARY & MAY

Tranexamic Acid + Glutathione Eye Cream

An eye-contour option containing 0.1% tranexamic acid (1,000 ppm), glutathione and niacinamide. Its TXA concentration is below the 2–5% range discussed in the facial melasma studies. Consider it supportive eye care; those trials do not establish its effectiveness for melasma or dark circles.

CHF 14.00
VIEW PRODUCT

Product ingredients, prices and stock were checked against the connected shop catalogue. The presence of TXA does not guarantee the results reported for other formulations in clinical trials. Daily sun protection remains essential. Product recommendations are not medical prescriptions.

Is tranexamic acid safe for sensitive skin and pregnancy?

Topical TXA is generally well tolerated in the small clinical studies available, although irritation, redness, dryness or stinging can occur. The final formulation matters: fragrance, other actives, solvents and high concentrations of niacinamide can influence tolerance. Patch testing and introducing one new product at a time are sensible if your barrier is reactive.

Topical and oral TXA have different safety considerations. Oral TXA affects systemic clotting pathways and is sometimes used off-label for melasma under specialist supervision. It requires assessment of thrombosis risk, medication interactions and other contraindications. A skincare blog is not a reason to start oral TXA.

For pregnancy or breastfeeding, high-quality pregnancy-specific safety data on topical TXA used for cosmetic pigmentation are limited. I would not label every TXA serum “pregnancy-safe” on that basis. Discuss individual products with your clinician; meanwhile, gentle skincare and consistent photoprotection remain the priority. Avoid retinoids during pregnancy.

Frequently Asked Questions

COMMON QUESTIONS · EVIDENCE-BASED ANSWERS

Does tranexamic acid actually fade dark spots?

It may help certain types of pigmentation, particularly melasma. Some randomized studies show improvement, but the overall evidence is heterogeneous and product-specific results are not guaranteed. Brown post-acne marks have less direct high-quality evidence than melasma.

Is 4% tranexamic acid better than 2%?

Not necessarily. Studies have used different concentrations, vehicles and delivery systems. A 2025 trial found improvement with both 2% niosomal and 5% conventional TXA combinations, but it did not isolate concentration as the reason for any difference. More percentage is not automatically more benefit.

Can I use tranexamic acid with niacinamide or vitamin C?

These ingredients can generally coexist in a routine, and TXA plus niacinamide has been studied in combination. However, tolerability depends on the complete formula and how many products you layer. Start one active at a time, especially with reactive skin.

How long before I notice a change?

Many clinical trials assess melasma after 8–12 weeks. Changes are gradual and individual. Daily photoprotection is essential, and recurrence remains common even after successful treatment.

Is tranexamic acid an AHA or exfoliating acid?

No. TXA is an antifibrinolytic molecule being investigated for pigment-related signalling pathways; it is not an AHA/BHA exfoliant. It can still irritate in some formulations.

Is a TXA serum safe during pregnancy?

Pregnancy-specific evidence for topical cosmetic TXA is insufficient for a blanket safety claim. Ask your clinician about the exact product and your circumstances. Sunscreen and gentle barrier care remain the safest foundations of a pregnancy pigmentation routine.

The dermatologist's verdict

Tranexamic acid deserves a place in the conversation about melasma. Its mechanism is plausible, and clinical trials—including a carefully designed 2025 formulation study—show meaningful improvements in some settings. But the 2026 systematic review reminds us that the overall evidence is not as tidy as skincare marketing would suggest. Mixed routes, different formulations, short follow-up and inconsistent controls make sweeping claims difficult to justify.

My preference is a well-tolerated, simple routine: appropriate daily photoprotection first, one targeted pigment-active second, and patience throughout. For persistent melasma, a dermatologist can help distinguish it from other pigmentary disorders and consider treatments with stronger evidence. The best serum is not the one with the loudest percentage on the box; it is the one that fits the diagnosis, the formulation and the person using it.

Innovation is welcome. Evidence is non-negotiable.


Scientific references

  1. Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies. Dermatol Ther. 2017;30(3). PMID 28133910. DOI 10.1111/dth.12465.
  2. Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20–31. PMID 12100180. DOI 10.1046/j.1365-2133.2002.04834.x.
  3. Ghasemiyeh P, et al. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma. Sci Rep. 2025 Nov 28;15:42739. PMID 41315336. DOI 10.1038/s41598-025-26693-8.
  4. Heidary B, et al. Randomized clinical trial on the efficacy of oral tranexamic acid versus topical tranexamic acid in treatment of melasma. J Cosmet Dermatol. 2025;24:e70428. PMID 40923777. DOI 10.1111/jocd.70428. Correction published November 2025 (PMID 41269746).
  5. Scabine Pessotti N, et al. The use of tranexamic acid to treat melasma: a systematic review and meta-analysis. Dermatol Ther. Published 6 Jan 2026. DOI 10.1155/dth/6691762. (Search update through January 2024.)
  6. Rahimnia A, et al. Efficacy of non-ablative fractional laser combined with tranexamic acid in melasma treatment: a randomized split-face trial. J Cosmet Dermatol. 2025;24:e70384. PMID 40776769. DOI 10.1111/jocd.70384.
  7. Polena H, et al. Comparison of visible light-protective tinted sunscreen to untinted sunscreen to protect melasma patients during summer. J Cosmet Dermatol. 2025;24:e70450. PMID 41014037. DOI 10.1111/jocd.70450.
  8. Janney MS, et al. A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma. J Cutan Aesthet Surg. 2019;12:63–67. PMID 31057273. DOI 10.4103/JCAS.JCAS_40_18.
  9. Sarkar R, et al. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2026;40:680–692. PMID 40996222. DOI 10.1111/jdv.70066.
Back to blog

Leave a comment